SRDX · Insider Trading
Surmodics, Inc. Common Stock
Every open-market purchase and sale reported by SRDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-19 | John D. Manders | VP Finance, Corp. Controller | D | −8,155 | — |
| 2025-11-19 | Joseph J. Stich | SVP of HR, President IVD | D | −61,631 | — |
| 2025-11-19 | Jose H Bedoya | Director | D | −30,008 | — |
| 2025-11-19 | Timothy J. Arens | Chief Financial Officer | D | −67,299 | — |
| 2025-11-19 | Gary R Maharaj | President & CEO | D | −192,056 | — |
| 2025-11-19 | Charles W Olson | SVP, Medical Device Coatings | D | −52,278 | — |
| 2025-11-19 | David Dantzker | Director | D | −40,183 | — |
| 2025-11-19 | Lisa Wipperman Heine | Director | D | −13,978 | — |
| 2025-11-19 | Gordon S. Weber | Sr. VP of Legal, GC and Sec. | D | −21,040 | — |
| 2025-11-19 | Susan E Knight | Director | D | −37,240 | — |
| 2025-11-19 | Teri Woodwick Sides | SVP, Vascular Interventions | D | −34,703 | — |
| 2025-02-20 | Lisa Wipperman Heine | Director | MIXED | +525 | −$28 |
| 2025-02-18 | Jose H Bedoya | Director | MIXED | +1,051 | −$31 |
| 2025-02-18 | David Dantzker | Director | MIXED | +1,059 | −$11 |
| 2025-01-28 | Susan E Knight | Director | MIXED | +2,092 | −$24 |
| 2024-12-06 | Joseph J. Stich | SVP of HR, President IVD | F | −1,034 | −$41.27K |
| 2024-12-06 | Timothy J. Arens | Chief Financial Officer | F | −1,265 | −$50.49K |
| 2024-12-06 | John D. Manders | VP Finance, Corp. Controller | F | −152 | −$6.07K |
| 2024-12-06 | Gordon S. Weber | Sr. VP of Legal, GC and Sec. | F | −668 | −$26.66K |
| 2024-12-06 | Charles W Olson | SVP, Medical Device Coatings | F | −959 | −$38.27K |
| 2024-12-06 | Teri Woodwick Sides | SVP, Vascular Interventions | F | −946 | −$37.75K |
| 2024-12-06 | Gary R Maharaj | President & CEO | F | −4,248 | −$169.54K |
| 2024-12-03 | Timothy J. Arens | Chief Financial Officer | F | −1,786 | −$70.46K |
| 2024-12-03 | Joseph J. Stich | SVP of HR, President IVD | F | −1,655 | −$65.29K |
| 2024-12-03 | Teri Woodwick Sides | SVP, Vascular Interventions | F | −1,312 | −$51.76K |
| 2024-12-03 | Charles W Olson | SVP, Medical Device Coatings | F | −1,534 | −$60.52K |
| 2024-12-03 | Gordon S. Weber | Sr. VP of Legal, GC and Sec. | F | −1,030 | −$40.63K |
| 2024-12-03 | John D. Manders | VP Finance, Corp. Controller | F | −387 | −$15.27K |
| 2024-12-03 | Gary R Maharaj | President & CEO | F | −6,470 | −$255.24K |
| 2024-11-27 | Timothy J. Arens | Chief Financial Officer | Sell | −7,009 | −$276.45K |
| 2024-08-23 | Gary R Maharaj | President & CEO | MIXED | +10,448 | −$30 |
| 2024-08-23 | Joseph J. Stich | SVP of HR, President IVD | MIXED | +1,851 | −$71.86K |
| 2024-08-20 | Charles W Olson | SVP, Medical Device Coatings | MIXED | +1,720 | −$57.64K |
| 2024-08-20 | Timothy J. Arens | Chief Financial Officer | MIXED | +1,718 | −$57.72K |
| 2024-02-12 | David Dantzker | Director | A | +1,803 | — |
| 2024-02-12 | Ronald B Kalich Sr | Director | A | +1,803 | — |
| 2024-02-12 | Jose H Bedoya | Director | MIXED | +2,781 | −$32 |
| 2024-02-12 | Susan E Knight | Director | A | +1,944 | — |
| 2024-02-12 | Lisa Wipperman Heine | Director | A | +1,803 | — |
| 2024-02-07 | Susan E Knight | Director | MIXED | +869 | −$16 |
| 2024-01-23 | David Dantzker | Director | MIXED | +1,159 | −$27 |
| 2024-01-03 | Ronald B Kalich Sr | Director | A | +491 | +$17.85K |
| 2023-12-29 | Ronald B Kalich Sr | Director | MIXED | +1,387 | −$19 |
| 2023-12-06 | Gordon S. Weber | Sr. VP of Legal, GC and Sec. | A | +6,539 | — |
| 2023-12-06 | Gary R Maharaj | President & CEO | A | +27,942 | — |
| 2023-12-06 | John D. Manders | Corporate Controller | A | +1,486 | — |
| 2023-12-06 | Charles W Olson | SVP, Medical Device Coatings | A | +6,302 | — |
| 2023-12-06 | Joseph J. Stich | SVP HR and IVD | A | +6,302 | — |
| 2023-12-06 | Teri Woodwick Sides | SVP, Vascular Interventions | A | +9,274 | — |
| 2023-12-06 | Timothy J. Arens | Chief Financial Officer | A | +8,323 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SRDX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.